For many patients with leukaemia or other malignant blood diseases, haematopoietic stem cell transplantation is the last and most effective treatment option. The procedure works: donor stem cells build a new immune system and destroy remaining tumour cells. But in 30 to 50 percent of cases, so-called graft-versus-host disease follows, in which the transplanted immune cells recognize the recipient's body as foreign and attack it. Researchers at the Fraunhofer Institute for Cell Therapy and Immunology (IZI) in Leipzig published a mechanism in January 2026 that could solve exactly this problem.
The Problem Behind the Success
Graft-versus-host disease, or GvHD, is the central unresolved problem of transplant medicine. When donor T cells attack the recipient's foreign tissue, the result is organ damage, skin reactions and severe infections. The standard treatment uses systemic immunosuppressants: medicines that dampen the entire immune system. This prevents rejection but also leaves patients vulnerable to all kinds of infections and can permanently damage organs. For many patients, GvHD is therefore not the end of danger but the beginning of another phase of suffering after an otherwise successful transplant.
The Solution: Prevention Before the Transplant
The research team led by Professor Stephan Fricke, director of the clinical network at Fraunhofer IZI, pursued a different approach. Rather than fighting the immune reaction after the transplant, the problematic immune cells are made immune-tolerant before the procedure. The tool: anti-CD4 antibodies applied to the donor T cells before they are transferred to the patient.
In laboratory and animal models, a single treatment was enough to prevent GvHD across the entire observation period. What does not happen is the crucial part. The general immune function of the cells is preserved. The transplanted cells can still recognize and destroy tumour cells, the so-called graft-versus-leukaemia effect that is essential for therapeutic success. Only the reaction against the recipient's tissue is selectively suppressed. The study appeared on 27 January 2026 in the journal Blood, the leading journal of international haematology.
Industrial Implications
Personalized cell therapies are considered one of the most important growth markets in biomedicine. European demand for CAR-T therapies and allogeneic transplants is growing at double-digit rates annually. Solving a problem that affects half of all transplant patients would have a direct impact on the number of patients who can benefit from these therapies in the long run.
What Research Does Not Yet Know
The current results come from laboratory and animal models. The transition to humans is the critical next step and is not yet complete. Clinical phase I/II trials are planned; a concrete start date has not been announced. The research group expects to apply for clinical-phase funding by the end of 2026.